The liver cancer drug market size is expected to grow from USD870 million (2017) to nearly USD4 billion (2027), which will benefit from the marketing of other 8 high-priced biologics and the extensive promotion of nivolumab as a first-line therapy.
The report to identify and analyse emerging trends along with major drivers, challenges and opportunities in the global influenza market. Also highlights key development and new drugs launched by various companies across the globe.